Boustead Securities Client True Leaf Raises $10 Million (CAD) via Reg A+ Completes First Reg A+ Offering By a Canadian-Listed Issuer

VERNON, BC , Jan. 25, 2018 (GLOBE NEWSWIRE) — Boustead Securities client True Leaf Medicine International Ltd. (“True Leaf” or the “Company”) (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) announced that it has raised $10 million (CAD) via a Regulation A+ offering. With the offering fully closed, True Leaf is the first Canadian-listed company to conduct a successful Regulation A+ offering.

True Leaf offered a total of 14,285,715 common shares at a price of C$0.70 per share, with a minimum subscription amount of C$350 (or 500 shares) per investor. The use of Regulation A+ allowed the Company to offer and sell its common shares to public retail investors as well as traditional accredited and institutional investors.  Boustead Securities, LLC was the lead underwriter, and the True Leaf offering was listed on www.FlashFunders.com .

“Boustead is proud to have assisted True Leaf in becoming the first Canadian-listed issuer to conduct a Regulation A+ offering” said Boustead CEO Keith Moore.

True Leaf Founder and Chief Executive Officer, Darcy Bomford, stated, “We’ve always wanted to give the people who love our products, and share in our vision and values, the chance to own a piece of True Leaf” said Mr. Bomford. “Regulation A+ gave us this opportunity. We believe the proceeds from this offering should put us in an excellent position to execute our business plan.”

Risks of Investment in True Leaf

An investment in True Leaf has a high degree of risk including the lack of a listed market for its securities in the United States as well as other risks common to Regulation A+ investments such as a small equity market capitalization and public float, which may impair the liquidity of this investment.   Moreover Canadian investors are unable to sell securities placed in the concurrent offering.  The Company can make no assurances about the success of its products, or its licensing or marketing efforts; consequently investors in True Leaf may lose some or all of their investments.  True Leaf does not have a license to produce cannabis.   Cannabis, marijuana, and any products containing THC and CBD are illegal in the United States of America, notwithstanding laws of several states to the contrary.  Further, transportation of such products across state lines or across national boundaries remains a Federal Offense in the United States of America, as well as the use of any federally chartered financial institution for transmittal or deposit of funds related to the sale of such products.  Accordingly, there can be no assurance that True Leaf will receive a license to produce cannabis from Health Canada, and even if it were to receive such a license, there can be no assurance that it can import its products into the United States for market or sale, or to repatriate the proceeds of such sales for the benefit of investors in this offering.

SEC Legends

An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that we may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits, or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from:

https://www.sec.gov/cgi-bin/browse-edgar?company=True+Leaf&owner=exclude&action=getcompany

Forward-Looking Statements

This news release contains forward-looking statements; and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we refer you to a more detailed discussion of the risks and uncertainties in the Company’s filings with the Securities and Exchange Commission when available. The forward-looking statements contained in this news release are made only as of today; and True Leaf Medicine International Ltd. is under no obligation to revise or update these forward-looking statements.

Media Contact:
Boustead Securities, LLC              
Keith Moore, CEO
keith@boustead1828.com
M: 949-295-1580

Leave a Reply

Your email address will not be published. Required fields are marked *